|Day Low/High||77.76 / 80.44|
|52 Wk Low/High||69.10 / 95.19|
The stock hasn't done anything wrong, but we need to be ready just in case.
The longer-term push is starting to lose steam and may need more consolidation than just a light-volume selloff.
Baxter will have to prove it can make a new high and still push higher.
In the weekly chart, it's in the strongest technical position seen for a long time.
Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.
There are some good buying ideas among these stocks.
Jim Cramer, portfolio manager at Action Alerts PLUS, and research director, Jack Mohr sat down to talk about one of the charitable trust’s newest positions.
Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
Beyond Greece, Puerto Rico and the June jobs report, Investors should also be aware of a big number of corporate spin-offs this week.
These new companies may offer some intriguing opportunities.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Baxter Shareholders will also get stake in new firm Baxalta.
I am selling my BAX long. I am selling my Baxter International (BAX) long based on my belief that the company might modestly miss fourth-quarter 2014 consensus expectations. If I am correct, this could lead to a guide down in 2015 expectations. More...
The biotech deals augur well. Today's Roche/InterMune deal (and the other biotech deals reported in the last month) should augur well for Baxter's (BAX) spinoff into two companies. BAX is a conservative play that has lagged the market and still repr...